[Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin].
To investigate the efficacy and safety of ezetimibe on uncontrolled LDL-C when added to ongoing statin therapy in patients with coronary heart diseases (CHD) and diabetes mellitus (DM). 61 patients with LDL-C level exceeding target goal (<2.07 mmol/L) after 12 weeks' treatment with statins, received ezetimibe in addition to their ongoing statin therapy for 8 weeks. Lipid parameters, alanine aminotransferase (ALT), aspartic aminotransferase (AST) and creatine kinase (CK) were compared before and after the adding of ezetimibe. LDL-C before and after the adding of ezetimibe was (2.74+/-0.43) mmol/L and (2.19+/-0.32) mmol/L, respectively (P=0.03) in 61 patients. Ezetimibe added to statin therapy significantly reduced the LDL-C level and TC level by additional 20.1% and 19.1%, respectively (P<0.05). 74% (45/61) patients treated with ezetimibe added to statin reached their target LDL-C goal. No change of TG and HDL-C was observed and no change of AST, ALT and CK was found either. Ezetimibe added to statin therapy lowered LDL-C level further and improved the goal attainment in patients with CHD and DM.